GPGrossPatternRESEARCH SYSTEM
SEC CHECK OPERATIONAL
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME

SBFM · Dec 31, 2025

Sunshine Biopharma Inc.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.

STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration

State dimensions

Filing0001683168-26-002644General Corporate
Capex intensity50thOwn-history percentile · N=12
Evidence method

Level · gp.fundamentals.capex_revenue_ratio

0.48% · OPTIONAL · VALID

Operating cash generation85thOwn-history percentile · N=20
Evidence method

Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue

-14.68% · OPTIONAL · VALID

Revenue growth5thOwn-history percentile · N=20
Evidence method

Yoy · gp.fundamentals.revenue

4.11% · CORE · VALID

Inventory pressure10thOwn-history percentile · N=20
Evidence method

Level · gp.fundamentals.inventory_revenue_ratio

37.11% · OPTIONAL · VALID

Gross margin30thOwn-history percentile · N=20
Evidence method

Level · gp.fundamentals.gross_margin

33.76% · CORE · VALID

Operating margin70thOwn-history percentile · N=20
Evidence method

Level · gp.fundamentals.operating_margin

-17.15% · CORE · VALID

R&D intensity10thOwn-history percentile · N=20
Evidence method

Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue

1.66% · OPTIONAL · VALID

As-filed lineage

Fundamental state history

Each observation is tied to the filing and facts available at that report date. Amendments remain separate.

History30 statesSelf-history eligible
Dec 31, 20214/7 normalizedLevel 3Mar 31, 20225/6 normalizedLevel 3Jun 30, 20226/6 normalizedLevel 3Sep 30, 20226/6 normalizedLevel 3Dec 31, 20226/7 normalizedLevel 3Mar 31, 20236/6 normalizedLevel 3Jun 30, 20236/6 normalizedLevel 3Sep 30, 20236/7 normalizedLevel 3Dec 31, 20236/7 normalizedLevel 3Mar 31, 20246/6 normalizedLevel 3Jun 30, 20246/6 normalizedLevel 3Jun 30, 20246/6 normalizedAmended as filedSep 30, 20246/6 normalizedLevel 3Dec 31, 20247/7 normalizedLevel 3Mar 31, 20257/7 normalizedLevel 3Jun 30, 20257/7 normalizedLevel 3Sep 30, 20257/7 normalizedLevel 3Dec 31, 20257/7 normalizedLevel 3Mar 31, 20267/7 normalizedLevel 3Jun 30, 20267/7 normalizedLevel 4
Period transition

What moved in the state?

Capex Intensity Increased
Previous
0.09%
Current
0.48%
Delta
0.40%
Cash Generation Decreased
Previous
-7.73%
Current
-14.68%
Delta
-6.96%
Growth Decreased
Previous
11.64%
Current
4.11%
Delta
-7.54%
Inventory Pressure Decreased
Previous
149.34%
Current
37.11%
Delta
-112.23%
Margin Increased
Previous
32.64%
Current
33.76%
Delta
1.12%
Profitability Decreased
Previous
-11.54%
Current
-17.15%
Delta
-5.61%
R And D Intensity Increased
Previous
1.27%
Current
1.66%
Delta
0.40%
Self-history only

Previous similar states

Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.

Not enough compatible prior states for a transparent self-history match.
Research Graph

Related governed research

Transitioned To · SBFM Fundamental State →Transitioned To · SBFM Fundamental State →Transitioned To · SBFM CAPEX_INTENSITY_INCREASED →Transitioned To · SBFM CASH_GENERATION_DECREASED →Transitioned To · SBFM GROWTH_DECREASED →Transitioned To · SBFM INVENTORY_PRESSURE_DECREASED →Transitioned To · SBFM MARGIN_INCREASED →Transitioned To · SBFM PROFITABILITY_DECREASED →Transitioned To · SBFM R_AND_D_INTENSITY_INCREASED →

Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.